Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the info. PBI was pursuing a west coast manufacturing site. This ought to help jump start their initiative for CBD/THC products.
Yeah. Uncle Bud's didn't/doesn't have the required State license to work with CBD, so they had/have a third party contract manufacturer do it---just like PBIO has Canopy CBD Farms do it for them. So PBIO inherited their contract manufacturer when they acquired Uncle Bud's. Voila, west coast manufacturer.
PBIO has a west coast manufacturing partner? Creme de Cana?
"PBIO finally looks ready pop really big. Their UltraSear and BaroFold are huge industry game changers and their is very little stock outstanding."
Dreamer!!! UltraShear's competitors were out years before PBIO even made their very first nano-emulsion (and cost about ¼ what PBIO wants). They've owned BaroFold for seven years, and it never once made a dent in the annual revenue or total loss. As far as “very little stock outstanding” goes, not for long. It went from $2.14 a year ago to $.26 today (-88%). Why, because of the constant daily dilution that happens while they pay bills with restricted stock---which is then sold 6 months later at a loss for the lenders.
PBIO finally looks ready pop really big. Their UltraSear and BaroFold are huge industry game changers and their is very little stock outstanding.
PBIO finally looks ready pop really big. Their UltraSear and BaroFold are huge industry game changers and their is very little stock outstanding.
$PBIO Pressure BioSciences Announces Closing of Uncle Bud’s Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales
https://www.globenewswire.com/news-release/2024/01/22/2813059/11282/en/Pressure-BioSciences-Announces-Closing-of-Uncle-Bud-s-Acquisition-in-All-Stock-Transaction-Completing-UltraShear-Nanoemulsions-Forward-Integration-with-World-Class-Marketing-Sales.html
SOUTH EASTON, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, today announced the closing of its acquisition of natural health and wellness leader Uncle Bud’s (“UB”) in an all-stock transaction. Incorporating UB’s 70+ already popular products, 865K member on-line community, existing sales channels online and with leading large retailers, enviable celebrity spokesperson relationships, and invaluable experience building successful consumer products businesses, PBIO will leverage and integrate the Company’s revolutionary UltraShear™ technology (UltraShear™ or UST™) platform for further improved nanoemulsified products that deliver industry-leading speed of action, effective dosing payload delivery, and long-term stability. With these unique product improvement and differentiation capabilities, PBIO intends to redefine the basis of competition in multiple major market sectors, and to become a leading provider of topicals and other consumer products.
Transaction Terms
Under the terms of the transaction, PBIO acquired all assets and assumed selected liabilities of UB. In addition, the parties agreed to an earnout for additional shares of PBIO Common Stock based on the achievement of revenue and pre-tax income results in 2024. Upon closing, all employees of UB became employees of PBIO and UB became the Consumer Products Business Unit of PBIO. More definitive transaction terms will be included in the Company’s upcoming SEC filings.
Significance of the Transaction
The transaction is expected to be immediately accretive and a major accelerator to PBIO’s top line revenue growth.
The combined companies will be ideally positioned to attract new growth investment, rapidly strengthen their balance sheet, accelerate PBIO’s path to profitability in 2024, and catalyze our drive to uplist to NASDAQ/NYSE.
The co-founders/senior management of UB are experts in branding, celebrity spokesperson management, and online and retail multimedia marketing.
UB will rapidly incorporate PBIO’s best-in-class Nano-CBD into their already highly renowned and successful CBD products, for new market breakaway potential!
Senior management of UB and PBIO are already planning a dozen new products that they believe could be formulated and released in 2024, just using PBIO’s existing UltraShear processed Nano CBD.
UB markets and sells many products in the health & wellness area that are unrelated to Hemp and CBD.
UB has an ongoing partnership with multi-Grammy award-winning Toni Braxton as a highly successful marketing ambassador – and Toni has announced that she is excited to continue as a PBIO/UB spokesperson going forward.
UB has been featured, as well as their hemp and CBD products, in an extensive variety of high profile news outlets and magazines online over the past several years: https://www.unclebudshemp.com/press/.
Expected Financial Impact
PBIO’s President and CEO, Richard T. Schumacher, summarized: “This transaction combines the existing momentum and ready market execution power of Uncle Bud’s with the pivotal scientific and product breakthrough of the UltraShear nanoemulsions processing platform for record-setting product performance and long-term stability. In 2024 alone, we are forecasting a 5-fold leap forward in PBIO revenues to over $10 million, but this is only a steppingstone towards revolutionary impact and sales growth that we expect to achieve across the nutraceuticals, cosmeceuticals, skincare, food/beverage, agrochemical, and other major markets in the following years.”
Jeffrey N. Peterson, PBIO’s Chairman, added: “Our Board and leadership team have carefully sought out this strategic combination of Uncle Bud’s marketing skill and power to combine with PBIO’s world class scientific innovation team. Specifically, this positions PBIO with a fast forward integration capability that will allow us to selectively set the timing and drive the pace of revolutionary change across multiple major markets. This rapid growth engine provides a central platform to leverage new growth capital, restructure and strengthen our balance sheet, and complete our drive to uplist to a national stock exchange in 2024.”
$PBIO Pressure BioSciences Reports New Client Launching Around UltraShear Nanoemulsions Platform with $300,000-plus Product Order
https://www.globenewswire.com/news-release/2024/01/18/2811755/11282/en/Pressure-BioSciences-Reports-New-Client-Launching-Around-UltraShear-Nanoemulsions-Platform-with-300-000-plus-Product-Order.html
SOUTH EASTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, and more, announced today the receipt of an Open Order Agreement for the purchase in 2024 of a minimum of 10,000 bottles (over $300,000) of the Company’s Nano-CBD Topical Spray, with an initial product shipment in the coming weeks, from the Company’s west coast manufacturing partner. Subsequent shipments will follow quickly thereafter.
VICAR Holdings, LLC (“VICAR”), the purchaser of this revolutionary Nano-CBD Topical Spray, has recently formed with a central health and wellness mission, focused on the on-line sale of only the highest quality and performance products, featured in a premium “PrescriptionGrade” product line. The company’s website and online store are currently under construction, with the initial PrescriptionGrade products slated for Beta testing in March 2024, and fully launching into sales in Q2 2024. VICAR has proudly announced PBIO’s Nano-CBD Topical Spray will be the first product available through their on-line store. The product will be sold as PrescriptionGrade Nano-CBD.
Manufactured using PBIO’s patented UltraShear™ technology (UltraShear™ or UST™), PrescriptionGrade Nano-CBD is a revolutionary high-performance product providing ultrafast speed of action and unprecedented effectiveness, in a preservative-free, “green/clean” labeled, sterile-filtered and vialed, all plant-based, highly stable topical product design. It is expected to quickly become the compelling natural choice for today’s health and environmentally conscious consumers.
John Hollister, PBIO’s Director of Marketing and Sales, added: “It’s great to come into a New Year with strong momentum. On the heels of our highly strategic Uncle Bud’s announcements over the past week, we see the contract with VICAR Holdings as a clear indication of the great things to come in 2024. Each of these contracts will expand the consumer experience pool, which will help spread the word about the quality and effectiveness of UltraShear-processed CBD. Based on the results in a recent peer-reviewed scientific journal article by Professor ElSohly (University of Mississippi), an acknowledged global natural products expert, we know that PrescriptionGrade Nano-CBD is positioned to become recognized as a top-performing CBD product worldwide – and VICAR customers will soon know this as well.”
Vince Caruso, Managing Member of VICAR Holdings, LLC, said: “Our innovative solution employs PBIO’s revolutionary UltraShear platform, which has been designed to optimize the speed of delivery and absorption of CBD and other oil-soluble nutraceuticals. Through meticulous craftmanship and cutting-edge technology, we elevate our products to “PrescriptionGrade™” standards, ensuring only the highest standards of quality and effectiveness. Our commitment to excellence extends well beyond the all-important formulation, encompassing iconic branding and streamlined order flow systems. With a focus on enhancing health and wellness, our strategy integrates cutting-edge scientific knowledge and professionalism to provide customers with superior tools for helping them achieve a healthier lifestyle.”
Ric Schumacher, President and CEO of PBIO, added: “VICAR has access to over 200,000 monthly website visitors and over 90,000 YouTube subscribers through existing businesses affiliated with Vince and members of his team. VICAR also has exclusive access to multiple billboards in Manhattan as well as thousands of media outlets throughout the U.S. and the world. Their online store will sell only the best of the best in health and wellness products. We are proud that PBIO’s Nano-CBD will be the first product featured on the PrescriptionGrade website and look forward to showcasing many additional PBIO nanoemulsified products during 2024, and beyond.”
“PBIO absolutely no question that they are the ONLY technology that actually works in terms of creating a new breed of oil drops sized so small (nano sized so small you can't see them). “ There's at least a dozen competitors that routinely create drops as low as 10-20 nm (droplets become invisible when they are less than 100nm).
“Nobody has ever been able to do this until PBIO.” Bull Sh*t----Industrial Sonomechanics has been doing it since 2017.
“This new device makes any oil based product absorb into the human or animal or plant body much much faster and better than ever before.” A study published in 2019 came up with similar results. And they used a cheap magnetic stirrer to create droplets in the 35nm range. PBIO's K45 ($200K+ ongoing royalty) needed six passes to get to 60nm. The rest if your post is just a uninformed, nonsensical, hopium fueled, daydream.
PBIO absolutely no question that they are the ONLY technology that actually works in terms of creating a new breed of oil drops sized so small (nano sized so small you can't see them). Nobody has ever been able to do this until PBIO. Look at the list of big and well-known names that buy there machines. Look at the studies done by the top CBD and THC researcher in world. This new device makes any oil based product absorb into the human or animal or plant body much much faster and better than ever before. This is beyond huge. Tis will impact dozens of multi-billion-dollar products fast. Unlike every disruptive technology that has to fight to be adopted, PBIO UltraShear will be PULLED into every oil based product almost overnight because EVERY company will want to beat their competitors BEFORE their competition beats them. Total no brainer here. Load up the truck. https://richardacavalli.wixsite.com/greenplanetmicrocaps/faster-acting-more-powerful-drugs
"Six more months before we see the light at the end of the tunnel."
Let's hope that light isn't from an oncoming train.
PBIO doesn't have a new way. There was a study published in 2019 that got the same results---with a magnetic stirrer no less. And that magnetic stirrer resulted in 35nm droplets---less than the 60nm droplets from the PBIO K45. PBIO isn't alone in the high-shear arena either---think microfluidics and ultrasound.. After reading the PBIO self-serving crap try doing some research. All PBIO's study did was raise the droplet threshold---allowing more competition.
$PBIO has new way to make CBD and THC work much faster and better. Works on many pharmaceuticals, nutraceuticals and cosmetics. Going to go mainstream fast. https://richardacavalli.wixsite.com/greenplanetmicrocaps/faster-acting-more-powerful-drugs
Six more months before we see the light at the end of the tunnel.
little monster in the making $$$$$$$$$$$
Anybody home? Looking like the bio availability study will be released soon(?) with their current price/volume activity.
Getting the awareness to the short in this stock. I believe a short squeeze is coming
Crickets! This space has gone silent when it should be lighting up! We're at the inflection point of this stock and not a peep from anyone. I'm Very Bullish!
Show me the money----on an 8k,with no safe harbor statement.....There's a reason they don't put their crap in an 8K, but only in PRs---safe harbor in PRs allow them to lie. 8Ks, not so much.
$PBIO Pressure BioSciences Invites Interested Investors to Attend a Webinar on the Health and Wellness Marvels of PBIO's Revolutionary UltraShear Platform
https://www.accesswire.com/774802/Pressure-BioSciences-Invites-Interested-Investors-to-Attend-a-Webinar-on-the-Health-and-Wellness-Marvels-of-PBIOs-Revolutionary-UltraShear-Platform
Webinar Scheduled for 11:00AM ET on Thursday, August 17; Nearly 500 Registrants to Date.
SOUTH EASTON, MA / ACCESSWIRE / August 17, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide nutraceuticals, cosmeceuticals, food & beverage, pharmaceuticals, biotherapeutics, agrochemical, and other industries today announced that the Company's President and CEO (Mr. Richard T. Schumacher) and Director of Marketing & Sales (Mr. John B. Hollister) are the featured speakers at an online webinar scheduled for 11am ET on Thursday, August 17, 2023.
The webinar is entitled: "Health and Wellness Innovations: The Marvels of UltraShear™". During this webinar, you can expect to:
Gain a quick overview of Pressure BioSciences Inc. (OTCQB: PBIO) and its core technologies and products.
Learn about the powerful UltraShear platform and why it is viewed as a "Best-in-Class" processing system.
Explore UltraShear's transformative impact through its multiple applications in health & wellness.
Be inspired by life-changing experiences enjoyed by users of products processed by the UltraShear platform.
Have your questions answered during our interactive Q&A session.
Don't miss out on this chance to be part of the future of innovation in Health and Wellness! Register here to secure your spot and learn more about the webinar:PBIO Aug 17 Webinar Registration.
PBIO Recent News and Accomplishments
PBIO Reports Strongly Accelerating UltraShear Nano-CBD orders.
PBIO to Evaluate Company's Patented UltraShear Process to Extend Shelf-Life of Fresh Produce.
PBIO's UltraShear Nano-CBD Commercial Rollout Program Enters Rapid Expansion Phase 2.
Company Announces Nano-CBD Topical Spray Distribution Agreement with Crème de Canna.
Key Academic Publication Further Validates PBIO's UltraShear Platform's Impact on Clean-Label Foods.
PBIO Partners with Somalab Int'l for Development and Distribution of UltraShear-enabled health products.
Consumer Testing Validates Rapid Absorption/Effectiveness of UltraShear Nano-THC Spray
Mr. Richard T. Schumacher, PBIO's President and CEO, commented: "The combination of our UltraShear launch progress, the powerful enhancement that UltraShear offers in multiple billion-dollar industries, the impending publication of UltraShear bioavailability study results, and efforts focused on the improvement of our balance sheet and future revenue, provide a powerful forward-focused opportunity for our investors. We continue to work with multi-billion-dollar international conglomerates, well-funded startups, and many companies in between, as we facilitate the adoption of UltraShear. We believe our IP Estate is worth many times our current enterprise value. During my professional career, I have priorly founded/co-founded three successful public companies, yet in my opinion, none had close to the potential that we have in PBIO. For these and other reasons, we believe PBIO's future is both exciting and bright."
$PBIO Pressure BioSciences Reports Strongly Accelerating UltraShear Nano-CBD Orders
https://www.accesswire.com/773314/Pressure-BioSciences-Reports-Strongly-Accelerating-UltraShear-Nano-CBD-Orders
Since Mid-July Launch into Aggressive Expansion Phase, Company Adds Five New U.S. Distributors and Secures Initial Market-Seeding Orders for Over $300,000 of Revolutionary UltraShear Nano-CBD Product
SOUTH EASTON, MA / ACCESSWIRE / August 9, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food and beverage, and other industries, announced today strongly accelerating orders for its UltraShear™-processed Nano-CBD topical spray product. In the three weeks following the Company's expansion into Phase 2 of its commercial roll-out, seven initial market-seeding orders for UltraShear Nano-CBD have been received from five new and two existing distributors. In all cases, the Company understands these product purchases represent pipeline fill for new branded product introductions, testing, and acceptance, and further anticipates the likelihood of substantial subsequent orders to follow throughout the remainder of 2023.
UltraShear Nano-CBD provides powerful product performance differentiation in a field over-crowded by confusing claims and hyperbole. The UltraShear process creates uniquely uniform and ultra-low nano-droplet sizes of hemp-derived CBD oil in water, creating a best-in-class, super-fast acting, highly bioavailable, all natural, preservative-free, and highly potent (40 mg/ml) Nano-CBD Topical Spray. PBIO has also recently disclosed the completion of important bioavailability studies in both academic and commercial settings, providing compelling supporting evidence for its "best-in-class" nanoemulsion performance. The Company anticipates imminent publication in a scientific peer-reviewed journal of research performed by a leading global cannabis academic research team, highlighting the vastly superior absorption and bioavailability of PBIO's UltraShear Nano-CBD versus the routinely available oral-GI absorption of current CBD formulations.
Mr. John B. Hollister, Director of Marketing and Sales, commented, "As previously explained, we strongly believe the marketplace has long been looking for a higher quality, effective, suitably nanoemulsified CBD product that can finally deliver fast and potent topical absorption of targeted benefits to users. The immediate response received from knowledgeable and experienced distributors, once they have been introduced to UltraShear Nano-CBD, has fully confirmed our expectations - they quickly ask for the opportunity to market our UltraShear-processed product."
Mr. Hollister continued: "We are confident that the powerfully differentiated consumer experience will provide the all-important adoption driver complementing our sales and marketing efforts. Our team will be attending multiple key industry meetings to facilitate greater UltraShear exposure to key CBD industry players and to add additional distributors. Our goal is to expand to 25 distributors prior to year-end, and 50 within 12 months. We believe each distributor will generate hundreds of thousands of dollars in annual revenue. Five new distributors and $300,000 in incremental revenue has been a gratifying start in the three-week period since launching our accelerated roll-out phase, but we believe it is just the "tip of the iceberg."
Mr. Richard T. Schumacher, President and CEO, commented: "We are highly disappointed in the Company's stock price, which in our opinion in no way reflects PBIO's present worth nor future potential. The combination of our UltraShear launch progress, the powerful enhancement that UltraShear offers in multiple billion-dollar industries, the impending publication of UltraShear bioavailability study results, and efforts focused on the improvement of our balance sheet and future revenue, together provide a powerful forward-focused opportunity for our investors. Management's faith in PBIO's future has been well-evidenced by our Chairman and my commitments of a large part of our personal net worths to PBIO. At the request of multiple employees, efforts are underway to institute an employee stock purchase plan to facilitate share acquisition by the staff. For these and many other reasons, we believe PBIO's future has never been brighter."
$PBIO Pressure BioSciences and Master Distributor Canopy CBD Farms Announce Major Increase in UltraShear Nanoemulsion Platform Pipeline
https://www.accesswire.com/770411/Pressure-BioSciences-and-Master-Distributor-Canopy-CBD-Farms-Announce-Major-Increase-in-UltraShear-Nanoemulsion-Platform-Pipeline
Rapid Q3/Q4 2023 Sales Growth Forecasted from North American Cannabis Retailers and Wholesalers
SOUTH EASTON, MA / ACCESSWIRE / July 26, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide nutraceuticals, cosmeceuticals, biotherapeutics, food/beverage, and other industries, announced today that Canopy CBD Farms LLC ("CCF"), the Company's Master Distributor for Cannabis Products in North America, has reported a significant increase in the pipeline of retailers and wholesalers engaged in negotiations for PBIO's UltraShear-processed nanoemulsions of CBD, THC, and other cannabinoids. One week ago, the Company entered the rapid expansion phase of its UltraShear Nano-CBD commercialization program (Phase 2). Working with the Company, CCF increased its short-term pipeline to over a dozen companies with strong interest in contracting for access to UltraShear nanoemulsified hemp and cannabis-derived products. CCF expects that half of these companies will generate purchase orders for UltraShear products/services over the next two weeks; the rest are expected to contract for UltraShear-processed products in a month.
Mr. John Westlake, President of CCF, emphatically stated: "There is a high level of excitement and interest in UltraShear-processed CBD nanoemulsions derived from hemp. Many customers now understand the clear advantages of the UltraShear platform and have been anxiously awaiting the transition to Phase 2, which would allow them to order UltraShear processed products. We believe the dozen companies added this week to our contracts pipeline are just the tip of the iceberg. We also believe that our contracts pipeline number will grow significantly as we transition further into commercialization Phase 2."
Mr. Westlake continued: "CCF is proud to announce that one of the most respected Key Opinion Leaders in the cannabis industry, John MacKay, Ph.D., has agreed to support CCF in a technical role. Dr. MacKay's experience and expertise is invaluable. He will help drive the adoption of the UltraShear platform through solid science and strong business acumen. We are honored to partner with Dr. MacKay as we pioneer the UltraShear platform release to the growing cannabis industry."
As the founder and CEO of Synergistic Technologies Associates, Dr. MacKay will leverage his more than 40 years of commercial and academic expertise to advance acceptance of the UltraShear platform in the cannabis industry. Dr. MacKay's perspective coupled with his extraction, separation, and formulation expertise will be valuable to all of PBIO and CCF's prospective cannabis industry business partners, ultimately benefiting the end users of UltraShear nanoemulsified cannabinoids. John MacKay (thecannabisscientist.com).
Six of the more exciting examples of opportunities being developed and negotiated by CCF are highlighted below, with deal closures expected over the coming days and weeks:
Research agreement with highly-respected MA company to evaluate quality of THC and CBD nanoemulsions.
Standing order for white label CBD spray bottles with a renowned Massachusetts dispensary.
Formulation agreement with specialty manufacturer and distributor of premium Phyto cannabinoid ingredients.
Product formulation and white label bottle contract with a well-known, hemp-based, global products cGMP manufacturer in the Mountain Region of the U.S.
Formulation and nanoemulsion ingredients supply to a Massachusetts-based cannabis beverage manufacturer.
White label contract with a large, mid-west, MS operator to market and sell PBI's unique Nano-CBD topical spray.
Mr. Richard T. Schumacher, President and CEO of PBIO, stated, "We are encouraged by the results from our partner CCF in their recent aggressive marketing of the UltraShear platform to new geographical areas and companies. It is exciting to see the expanding interest generated, which we believe will manifest itself in rapidly increasing revenue in Q3/Q4 2023."
Mr. Schumacher concluded: "With recent advances in our technology base, and in our current UltraShear commercialization roll-out, we believe PBIO's future has never been brighter. We are highly disappointed in the Company's stock price, which we believe in no way reflects PBIO's present worth nor its future potential. As evidence of management's faith in PBIO's future, Jeff Peterson (Chairman) and I have committed a large part of our personal net worth to PBIO. As evidence of our staff's faith in PBIO's future, and upon the request of multiple employees, efforts are being made to institute an employee stock purchase plan to facilitate share acquisition by the staff. During my professional career, I have priorly founded/co-founded three successful public companies, yet in my opinion, none had close to the potential that we now have in PBIO."
$PBIO Pressure BioSciences Launches Program to Evaluate Company's Patented UltraShear Process in Breakthrough Application to Extend Shelf-Life of Fresh Produce
https://www.accesswire.com/770160/Pressure-BioSciences-Launches-Program-to-Evaluate-Companys-Patented-UltraShear-Process-in-Breakthrough-Application-to-Extend-Shelf-Life-of-Fresh-Produce
Scientific Publications Demonstrate Effectiveness of CBD and Essential Oil Nanoemulsions in Shelf-Life Extension of Fruits and Vegetables; PBI Initiating Studies with Industrially Scalable UltraShear Nano-CBD
SOUTH EASTON, MA / ACCESSWIRE / July 25, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide food and beverage, agrochemicals, nutraceuticals, cosmeceuticals, biotherapeutics, and other industries, announced today the initiation of studies to evaluate and demonstrate its industrially-scalable UltraShear Technology™ ("UltraShear™") platform for producing oil-in-water nanoemulsions in the preparation of edible coatings of Nano-CBD to extend the shelf life and preserve the quality of fruits and vegetables.
Edible coatings are commonly used to enhance the quality and increase the shelf life of fruits and vegetables. However, industrial-scale use of edible coatings has struggled with effectiveness limitations due to poor stability and solubility of the coatings. Recent developments in nanoemulsion-based coating technology offer promise for an effective and efficient strategy but have been challenged by industrial-scaling limitations as well as quality and stability inconsistencies from current nanoemulsion technology platforms. The extremely low and consistent nano-droplet size distributions and stability achieved by PBIO's UltraShear platform, and its easy process scalability, offer exciting promise as a preferred platform for delivering and standardizing these innovative quality and preservation solutions for produce.
Cannabidiol ("CBD"), the primary non-psychotropic ingredient in cannabis or hemp plants, is now approved by the FDA for the treatment of seizure conditions. CBD has enjoyed much wider use for treatment of pain and disorders from ~4000 BCE in China to its rapidly widening modern popularity in treating pain, anxiety, sleep disorders and much more. For over two decades, studies have demonstrated CBD's antimicrobial effectiveness against human pathogens and more recently against plant pathogens (especially fungi associated with rot development in produce). These studies are now generating great interest among consumers increasingly focused on all natural and organic, preservative-free, "green-label" foods, and for investors focused on solutions for the enormous agricultural industry segment.
A recent peer-reviewed article ("Influence of a Transparent and Edible Coating of Encapsulated Cannabidiol Nanoparticles on the Quality and Shelf Life of Strawberries") published on May 4, 2023 in the American Chemical Society (ACS) Journal of Applied Materials and Interfaces focused on the antimicrobial activity of strawberries coated with CBD-infused nanoparticles. The article reported on the results of treated/untreated strawberries, showing that the CBD-treated samples ripened and decayed much more slowly than the untreated ones. Other scientific articles with similar results on nanoemulsified CBD, essential oils, and other natural additives have also been recently published advanced edible coatings.
Mr. John Hollister, Director of Marketing and Sales for PBIO, noted: "We are now awaiting the publication in a scientific peer-reviewed journal of recent research performed by a leading global cannabis academic research team contrasting the vastly superior absorption and bioavailability of PBIO's UltraShear Nano-CBD versus the routinely reported oral-GI absorption of current CBD formulations. In light of these results, we are now embarking on studies of UltraShear Nano-CBD as an optimal effective strategy for a new generation of all-natural, edible food coatings."
Mr. Richard T. Schumacher, PBIO's President and CEO, concluded: "We have been delighted by recent inquiries from investors and food processing groups, who recognize our UltraShear platform as the preferred, best-in-class solution for the development of the highest quality, industrially-scalable, and long-term stable nanoemulsions of CBD and essential oils."
Mr. Schumacher continued: "We are excited about our obvious prospects for a leadership role in this important and growing applications area. Of course, this is only one of a myriad number of major market opportunities for our UltraShear platform, spanning nutraceuticals, cosmeceuticals, agrochemicals, pharmaceuticals, and the food/beverage sectors. Our UltraShear Nano-CBD is already fully formulated, soundly tested, recently launched into human topical and soon oral applications, and is ready for prime time!"
Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide nutraceuticals, cosmeceuticals, biotherapeutics, food and beverage, and othe ...
https://finance.yahoo.com/news/pressure-biosciences-announces-ultrashear-nano-135500905.html?.tsrc=rss
$PBIO Pressure BioSciences Announces UltraShear Nano-CBD Roll-Out Program Enters Rapid Expansion Phase of Distribution and Partnering
https://www.accesswire.com/768314/Pressure-BioSciences-Announces-UltraShear-Nano-CBD-Roll-Out-Program-Enters-Rapid-Expansion-Phase-of-Distribution-and-Partnering
During Interview with "Cannabis Talks" (Cannabis and Hemp Insider), CEO Ric Schumacher Reveals Transition into Aggressive Growth Phase for Revolutionary Nano-CBD with U.S. Retailers and Wholesalers
SOUTH EASTON, MA / ACCESSWIRE / July 17, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide nutraceuticals, cosmeceuticals, biotherapeutics, food and beverage, and other industries, announced today in an interview with renowned cannabis business authority Jeffrey Friedland that PBIO was now advancing into Phase 2 of commercialization of its revolutionarily-effective, UltraShear™-processed nanoemulsified CBD topical spray, transitioning from early, targeted sales and marketing efforts into rapid expansion plans for its nationwide and global distribution base.
Jeffrey Friedland, the CEO of FC Global Strategies and a thought-leader in the cannabis, hemp and CBD industries, is an author quoted in publications including the Wall Street Journal, New York Times, USA Today, Forbes, Bloomberg TV, NBC.com, and other leading business periodicals, a sought-after speaker at conferences globally, and is the host of online interview programs including "Business Connect Insider," "Medical and Pharma Insider," "Emerging Technology Insider" and "Cannabis and Hemp Insider." Click here to hear Mr. Friedland's interview with PBIO's President and CEO, Mr. Richard T. Schumacher: PBIO Video Interview July 16, 2023
Mr. Schumacher explained in the interview: "There has been significant noise in the CBD and broader cannabis markets from companies touting a nanoemulsion offering in the past few years, but none are able to match UltraShear's capability to deliver tightly controlled nano-droplet sizes in the sub-100 nm range, with rock-solid stability, easily and affordable scaled-up production efficiency, and elimination of the metal contamination resulting from the most commonly-used competitive technology today. We initially hand-picked a small, select group of retailers for our first round of efforts in the sale and distribution of our Nano-CBD Topical Spray product, which allowed us to explore and optimize factors like product formulation, CBD concentration targets, bottle and dispenser technology, product size and packaging configuration, pricing, and shipping logistics. This first phase of activity was extremely productive in answering those questions. We now have a confidently-designed product and an accumulation of powerful UltraShear Nano-CBD Topical Spray user testimonials."
Mr. Schumacher continued: "Effective this week, we enter PBIO's Phase 2 of our Nano-CBD commercialization strategy with rapidly expanding efforts to welcome and integrate many additional retailers and wholesalers across the USA, while we introduce and establish our uniquely fast-acting and potent Nano-CBD topical spray to the broader U.S. and global markets. As we have mentioned in recent news releases, independent research by a leading cannabis academic team has dramatically confirmed our UltraShear-processed Nano-CBD product to have uniquely differentiated performance over all existing known CBD products (compared to the gold standard of IV infusion), and we anticipate the release of those results in a peer-reviewed scientific journal in the near future."
Pressed by Mr. Friedman to discuss the expected impact of this announced Phase 2 upon PBIO's business results for the remainder of 2023 and beyond, Mr. Schumacher concluded: "We anticipate signing up over 20 retailers and wholesalers in the remainder of 2023, with an estimated incremental revenue impact of $2-3 million over 2022 results. We also plan to launch our UltraShear Nano-CBD Oral Spray product this October. Over the next 12 months, our goal is to sign and launch at least 50 new UltraShear Nano-CBD retailers and wholesalers, and to achieve at least $10M in incremental revenue impact in 2024. This is a very exciting transition time for our team, our investors, and for the world of CBD and cannabis users!"
$PBIO CEO Richard Schumacher and John Hollister, Director of Marketing and Sales, provide an update on the Company and progress on their revolutionary new platform, Ultra Shear Technology(TM)
"UST can be used for formulating stable dispersions without the need for any synthetic emulsifier or stabilizers. The knowledge obtained in the present study will facilitate process development of novel clean-label dairy-plant protein dispersions and design the UST equipment."
$PBIO Pressure BioSciences Announces UltraShear Processed Nano-CBD Topical Spray Distribution Agreement with Premier CA Cannabis Partner Crème de Canna
https://www.accesswire.com/766457/Pressure-BioSciences-Announces-UltraShear-Processed-Nano-CBD-Topical-Spray-Distribution-Agreement-with-Premier-CA-Cannabis-Partner-Crme-de-Canna
PBIO Adds CA Based Cannabis Quality, Innovation, and Social Equity Leader Crème de Canna to List of Distributors Selling PBIO's Ultra-Fast Acting and Highly Effective All-Natural Nano-CBD Topical Spray
SOUTH EASTON, MA / ACCESSWIRE / July 10, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food and beverage, and other industries, and Crème de Canna (CdC), a Santa Cruz County based leader in the development, manufacture, and supply of premium quality and innovative cannabis products, today announced their commercial agreement for the supply and distribution of PBIO's UltraShear™-processed nanoemulsified CBD ("UltraShear Nano-CBD") in a hemp-derived, best-in-class, super-fast acting, highly bioavailable, all natural, preservative-free, and highly potent (40 mg/ml) Nano-CBD Topical Spray.
Mr. Jeffrey N. Peterson, PBIO's Chairman, explained: "CdC's founding partners were among the earliest innovators in California's emerging cannabis industry. Their relentless focus on controlling quality from plant selection and growth through to product design, manufacture, and finished products has distinguished and equipped them for survival and success through the tumultuous history of this industry. Since its formal founding in 2010, Crème de Canna has been recognized as the oldest "social equity" licensed manufacturer and distributor of cannabis products in CA. In addition to their web-based marketing and distribution capabilities in CA and beyond, they have recently partnered with Catalyst, a leading chain of California dispensaries, providing CdC with a new, highly respected, and successful sales channel."
Mr. Peterson continued: "CdC's history, principles, and performance made them an attractive partner for our early efforts in developing and testing UST-processed nanoemulsified THC oral spray products in CA. Their team has worked closely with us to produce small batches of Nano-THC Oral Spray for consumer focus group testing, with notable success reported in several previous PBIO press releases. Upon PBIO's recent development and release of a Nano-CBD Topical Spray with our first few distribution partners, it was an obvious next step for the CdC team to partner with us to seize the opportunity to lead as a CA-based distribution partner."
Mr. Jonathan Kolodinski, Founder and CEO of CdC, commented: "For the first time ever, the opportunity to purchase Creme de Canna products outside of California has arrived. Crème de Canna is bringing its long-established domain expertise in crafting innovative, high-quality cannabis products in CA to new frontiers. We plan to actively distribute this new, UltraShear-processed, super-fast acting, high potency, and highly bioavailable Nano-CBD Topical Spray worldwide wherever CBD commerce is legally allowed. We are delighted to add this best-in-class Nano-CBD Topical Spray to our product line! Our team is excited about our partnership with PBIO and the opportunities they are opening with their disruptive UltraShear technology platform, now being introduced for cannabis products. CdC will be quickly launching this preservative-free, all plant-based Nano-CBD topical spray on our website, thus making this unique product available soon for purchase from CdC nationwide."
Mr. Richard T. Schumacher, President and CEO of PBIO, added: "This agreement between our companies for the supply and distribution of PBI's stable, highly absorbable UltraShear Nano-CBD Topical Spray is for a minimum of two years and is expected to generate over $1.0 million in revenue for PBIO in the first year alone. Jonathan Kolodinski has been an early and courageous innovator in the cannabis field in California and is a proven winner in this challenging growth industry. We are honored and excited to partner with Jonathan and his team at Crème de Canna on this next generation UltraShear Nano-CBD product, and likely on additional products to follow."
Read the publication and you will see that the results are um size droplets, and not nm size droplets (Hint a um is 1,000 times bigger than a nm). Any old homoginizer, emulsifier, microfluidics, or mixer that can produce um size droplets will do. Nano-emulsifiers are not necessary. The alternatives to PBIO are a tiny fraction of the cost and don't ask for an ongoing royalty to boot. As usual----much ado about nothing.
$PBIO Key Academic Publication Further Validates Pressure BioSciences UltraShear Platform’s Impact in Clean-Label Functional Foods & Beverages
https://www.accesswire.com/765956/Key-Academic-Publication-Further-Validates-Pressure-BioSciences-UltraShear-Platforms-Impact-in-Clean-Label-Functional-Foods-Beverages
Critical Enabling Role for UltraShear Processing in the Burgeoning Alternative Plant-Based and Ready-to-Drink Beverage Markets Highlighted in Published Study by The Ohio State University
SOUTH EASTON, MA / ACCESSWIRE / July 6, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences, nutraceutical, food and beverage, and other industries reported the publication in a high impact, peer-reviewed scientific journal of powerful confirmation that the Company's UltraShear™ Technology platform delivers uniquely transformational capabilities for addressing leading industry and consumer trends in food & beverage markets.
According to a recent market study by Grand View Research, the global plant-based beverages market was valued at $24.4 billion in 2021 and is projected to continue strong expansion at a 12.7% compound annual growth rate (CAGR) from 2022 to 2030 (global plant-based beverage market). The growing demand for plant-based beverages, such as non-dairy milk and smoothies, is driven by their health benefits, nutritional properties, and minimization of carbon footprint and environmental impact, making them popular among health-conscious individuals, the large and growing lactose-intolerant population, and the exploding growth in the vegan consumer segment driven by animal welfare and environmental stewardship concerns.
To address these challenges amid growing drought crises impacting global agriculture, the beverage industry is seeking sustainable solutions that harness the potential of drought-resistant crops as a source of plant protein. Peas, in particular, have gained significant attention within the functional beverage industry due to their robust sustainability and numerous health benefits. These gluten-free legume crops provide a sustainable source of plant protein, and aid in improving cholesterol levels, regulating blood glucose levels, and offering high dietary fiber content.
The development of new plant-based milk substitutes faces inherent challenges. Plant proteins are generally far less soluble than dairy milk proteins. Additionally, many current plant-based milk substitutes are often perceived as less appealing to consumers due to their proclivity for separation of fats from proteins - as often observed in protein-based beverages with separation and sedimentation of pea protein particles, rendering the beverage less visually appealing, less nutritious, and less enjoyable to consume.
Revolutionary reversal and control over these undesirable behaviors was demonstrated for the UltraShear platform in the recent publication by an internationally recognized team of Ohio State University researchers (Current Research in Food). Their study investigated the impact of UltraShear processing on the stability, texture, and taste of plant protein dispersions. The results were momentous regarding the impact of UltraShear, delivering pea protein dispersions that remained stable and free from phase separation or sedimentation. In addition, certain combinations of protein and lipid additives processed using UltraShear directly optimized product viscosity, eliminating the need for additional thickeners. Furthermore, the UltraShear platform capably created stable low droplet size nanoemulsions of fats, for further enhancement of the nutritional and sensory characteristics of these beverages. Overall, the publication recognized UltraShear's immense potential for development of new hybrid dairy-plant protein beverages or purely plant-based categories that are organic, non-GMO, high in protein content, easy to digest, and free of chemical additives and preservatives.
Dr. Edmund Y. Ting, PBIO's Senior VP of Engineering and a recognized world expert in high pressure food processing, commented: "We are delighted by this recognition and additional validation of UltraShear's potential to revolutionize the production of stable and appealing plant-based beverages. By leveraging this cutting-edge technology, PBIO is poised to help beverage companies with equipment and processing offerings that enable a new generation of innovative and sustainable beverages that meet the increasing global demand for healthy and environmentally-responsible, natural, organic, and clean label products."
Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: "The global plant protein beverage market is expected to grow to an impressive $41 Billion by 2027 (MDC Market Report), with the pea protein market alone growing to about $2.9 Billion (Pea Protein Market). Armed with these newly published research results on UltraShear's enabling capabilities, our internationally-renowned colleague Professor V.M. "Bala" Balasubramanian and colleagues at The Ohio State University are leading the way in contacting select U.S. and global food and beverage companies, to introduce them to the UltraShear platform, the Ohio State-PBI food industry consortium, and to PBIO for business partnering discussions that could develop into new leadership opportunities in the burgeoning alternative plant-based and ready-to-drink markets."
$PBIO Pressure BioSciences Announces Agreement with Somalab Int’l for Development & Distribution of UltraShear-Enabled Nanoemulsified Health and Wellness Products
https://www.accesswire.com/765651/Pressure-BioSciences-Announces-Agreement-with-Somalab-Intl-for-Development-Distribution-of-UltraShear-Enabled-Nanoemulsified-Health-and-Wellness-Products
Somalab to Enhance Existing and New Products with PBIO's UltraShear Platform.
Somalab to Immediately Begin Distribution of PBIO's Best-in-Class Nano-CBD Topical Spray.
Companies to Collaborate on Development & Sale of Novel, UltraShear-Enhanced Brain Boost Supplement.
SOUTH EASTON, MA / ACCESSWIRE / July 5, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide nutraceuticals, cosmeceuticals, biotherapeutics, food and beverage, and other industries, and Somalab International LLC ("Somalab"), a Texas-based leading supplier of novel health and wellness products throughout the U.S., today announced the execution of an agreement (the "Agreement") for the collaborative development and distribution of UltraShear™ Technology (UltraShear™)-enhanced health and wellness products.
Under the Agreement, the companies will (i) use the UltraShear platform to increase the already high quality of existing Somalab products to even higher, next-generation levels; and (ii) collaborate to develop new products that offer this same next-generation level of quality, including an enhanced "Brain Boost" product. Somalab will also immediately begin distribution of PBIO's best-in-class, preservative-free, 100% plant-based, and highly bioavailable Nano-CBD topical spray.
Mr. Earl Green, CEO and Founder of Somalab, commented: "In our never-ending pursuit of excellence, we recently discovered PBIO and their UltraShear technology. We quickly learned how and why their patented UltraShear platform delivers the best-in-class nanoemulsification solution available worldwide. We are thrilled to begin the announced collaboration, which will include enhancements to several of our products that already provide leading quality performance levels, as well as the introduction of their unique Nano-CBD topical spray to the thousands of customers in our data base."
Mr. Green continued: "We are also very excited about collaborating with PBIO on the development of a next-generation Brain Boost product. Our current Brain Boost Caps are one of our best sellers. But even a "best seller' can be enhanced, which we fully expect from the nanoemulsions resulting from UltraShear processing. Brain health is very important, but it can be hard to recover and/or maintain as we grow older. Fortunately for our customers, we believe that UltraShear processed nanoemulsions will enhance our already powerful and effective Brain Boost products."
Mr. Richard T. Schumacher, PBIO's President and CEO, commented: "This is a tremendous opportunity for both companies. Somalab benefits with immediate sales from PBIO's preservative-free, all plant-based, highly bioavailable, and best-in-class Nano-CBD topical spray. PBIO benefits from significant incremental revenues expected from these sales. Both companies benefit by incorporating UltraShear processing into Somalab's existing and future product line."
Mr. Schumacher added: "We believe Somalab's sale of our Nano-CBD will add over $200,000 in revenue for PBIO in 2023 and more than $1,000,000 in 2024. As exciting as that forecast is, we believe sales of an UltraShear-based, next-generation Brain Boost product could easily eclipse sales of Nano-CBD during 2024 - and Somalab is already suggesting additional products that could exceed our forecast for the UltraShear-enhanced next-generation Brain Boost product."
Mr. Schumacher concluded: "In addition to announcing this very exciting and profitable partnership with Somalab, we have also recently closed on several additional business transactions that will be announced in the coming days - transactions that we believe will also have significant impacts on our sales and growth during the second half of 2023, and beyond."
$PBIO Pressure BioSciences Invites Stakeholders, Fund Managers, and Investors to Attend a Webinar on PBIO's Revolutionary UltraShear Technology Platform
https://www.accesswire.com/763817/Pressure-BioSciences-Invites-Stakeholders-Fund-Managers-and-Investors-to-Attend-a-Webinar-on-PBIOs-Revolutionary-UltraShear-Technology-Platform
Webinar Scheduled for 4:30PM EST on Tuesday, June 27; Over 1,900 Registrants to Date.
SOUTH EASTON, MA / ACCESSWIRE / June 26, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide pharmaceuticals, biotherapeutics, nutraceuticals, cosmeceuticals, agrochemical, food & beverage, cannabis, and other industries today announced that the Company's President and CEO, Mr. Richard T. Schumacher, is the featured speaker at an online webinar, scheduled for Tuesday, June 27, 2023.
The webinar is entitled: "From Concepts to Success: Pressure BioSciences UltraShear™ Platform Revolutionizing Cannabis, Nutraceuticals, Cosmeceuticals, and Multiple Other Industries."
During this webinar, you can expect to:
Gain a quick overview of Pressure BioSciences Inc. (OTCQB: PBIO) and its core technologies and products.
Learn about the powerful UltraShear Technology platform and its transformative impact on various industries.
Get insights into Pressure BioSciences' Q1 2023 record financial results and future prospects.
Have your questions answered during our interactive Q&A session.
Don't miss out on this chance to be part of the future of innovation! Register here to secure your spot and learn more about the webinar:PBIO Webinar Registration 6.27.23
$PBIO Pressure BioSciences Partners with Veterans Service Team to Offer Exclusive Access for VST Members to a Unique, Custom-Made, UltraShear Nano-CBD & Other Products
https://www.accesswire.com/760844/Pressure-BioSciences-Partners-with-Veterans-Service-Team-to-Offer-Exclusive-Access-for-VST-Members-to-a-Unique-Custom-Made-UltraShear-Nano-CBD-Other-Products
VST Mission is to Serve Current and Past Members of US Armed Services and Coast Guard Through World-Class, Highly Effective, and Natural Wellness Products that Benefit the Mind, Body, and Soul
SOUTH EASTON, MA / ACCESSWIRE / June 13, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the global nutraceuticals, biotherapeutics, cosmeceuticals, agrochemical, and food/beverage industries, among others, and the Veterans Service Team ("VST") (www.vst.org), a self-funded, 501(c)3 non-profit company dedicated to the support and wellness of active duty and former members of all branches of the US Military and US Coast Guard, today announced a long-term (5-year) development and supply agreement between the companies.
PBIO's Ultra Shear Technology™ (UltraShear™ or UST™) platform allows oil-soluble active molecules like CBD to be prepared into nanoemulsions of vanishingly tiny oil droplets in water that ensures rapid absorption and unparalleled bioavailability of the CBD (or other active ingredients) into the water-based biochemistry of human bodies. The PBIO-VST partnership offers VST membership exclusive access to custom-designed, hemp-derived, UltraShear-processed nanoemulsions of CBD oil in water ("Nano-CBD"), providing unparalleled speed of action and reliable dosage delivery. As new UltraShear-processed nanoemulsified wellness, beauty, and nutraceutical products are developed and become available, these too will be readily offered to VST members, some of them also on an exclusive basis.
Mr. Howard Zall, COO of VST, commented: "Our mission is to serve the roughly 18 million current members and veterans of the US Armed Services and Coast Guard with education, support services, and a potent collection of diverse, carefully selected wellness products. We are in the early stages of building our membership, through which we expect to increase VST to over 2 million members in the next five years. It is our sincere honor to serve our Nation's Heroes."
Mr. Zall continued: "A leading-quality CBD product with world class speed and completeness of effectiveness has been the most important new offering that we have been targeting for our growing VST member base in 2023, to help address and manage their diverse, critical needs. Following extensive due diligence, we determined PBIO's UltraShear Technology was the world's leading platform for developing highly effective nanoemulsions of CBD in either a topical or oral spray. For VST, both formulations will be custom-developed and packaged by PBIO. In addition to being preservative-free, plant-based, all natural, fast-acting, highly bioavailable, and extremely potent CBD products, the products will be configured with unique features only available to VST members. We are very excited to partner with PBIO, and to soon introduce to our membership our first collaborative product: a revolutionary, one-of-a-kind, nanoemulsified CBD topical spray."
Captain George Ackerson, CEO and Founder of VST, and a two-tour veteran - Vietnam (circa 1971) as a Warrant Officer special operations scout helicopter pilot, and (circa 1978) as a Commissioned Officer in aviation maintenance and attack helicopter test pilot, stated: "Initially, we will be launching our custom-designed, one-of-a kind, UltraShear Nano-CBD Topical Spray, with its sister product (UltraShear Nano-CBD Oral Spray) to quickly follow. These unique products, to be available exclusively to VST members only, will be superbly targeted to address large and important unmet needs within the U.S. active military and veteran's communities. Results to date have demonstrated PBIO's UltraShear nanoemulsion processing capabilities go far beyond other so-called nano products currently on the market - with performance significantly better than we could have ever dreamed. We are very proud to partner with the amazing innovation team at PBIO."
Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: "We at PBIO have tremendous respect for George, his Team, and the VST mission. One-hundred percent of all VST efforts support current and past members of the US Armed Services and Coast Guard; in addition, VST donates 100% of its profits to veteran's charities and to Animal ‘Rescue' Shelters across the US. We are truly honored to announce this partnership and to provide the VST membership with a new, unique line of UltraShear nanoemulsified CBD products, as well as other wellness, beauty, and nutraceutical products in the future."
Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: "With VST's membership expected to exceed 2 million of the nearly 18 million active-duty personnel and veterans within five years, PBIO and VST are estimating PBIO's incremental revenue from this relationship will grow significantly year-over-year, from initial annual revenue of about $1.5M to revenue topping $15M in the fifth year of the agreement. These projections are for Nano-CBD products sales only, which the companies believe will be generated from sales of up to 50,000 spray bottles in Year 1 to approximately 500,000 spray bottles in Year 5. PBIO investors and VST members can expect to hear much more about additional UltraShear processed products offered through VST in the weeks and months ahead."
No! "Short" here,
They continue to sell their UST process and continue raise capital to increase their production capacity for their future sales.
It should be remembered that this Company continues to ignore selling their "product" to customers, and continues to exclusively spend money trying to attract investors. Not a good thing for business growth.
About New to the Street:
“The TV program provides the CEOs or executives of a company with a platform to explain to the audience about their company, their product, goals, roots, visions, and more. ….This gives a potential investor lot of data and information helping them decide whether they want to invest in the company and its product or not.”
From the disclaimer portion of their website (New to the Street):
“It should be understood that companies (clients) on the show pay a minimum of $350,000 for a 12 Part Series that guarantees over 60 Linear Television Broadcasts on multiple networks and over 70 commercials per quarter ( 3 month period) There is also monthly production fees charged averaging $5000 per month.”
$PBIO Pressure BioSciences Updates Forecast with Six Key Goals for June 2023 with Expected Multi-Million Dollar Growth Increments in FY 2023 and Beyond
https://www.accesswire.com/758611/Pressure-BioSciences-Updates-Forecast-with-Six-Key-Goals-for-June-2023-with-Expected-Multi-Million-Dollar-Growth-Increments-in-FY-2023-and-Beyond
SOUTH EASTON, MA / ACCESSWIRE / June 1, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food and beverage, and other industries today highlighted the six key goals they expect to achieve during the month of June 2023, and discussed the significant financial impact expected to result for the Company in FY 2023 and beyond. The top six goals expected to be completed in June include:
1. Addition of Three $1M+ (Annual) Nano-CBD Commercial Distribution Contracts
Leading Retailer (CBD Supply MD) recently introduced NanoBloom CBD to their multi-state client base.
PBI believes the Agreement with CBD Supply MD will be worth $1.5M+ over the next 12 months.
PBI anticipates three additional CBD retailers with similar revenue potential to close during June 2023.
2. Sale of Two Licenses ($1M+) for PBI's Patented UltraShear™ Platform for Nano-THC Processing
Multiple groups are negotiating a possible purchase of a 3-year exclusive THC processing license for a state.
PBI anticipates the sale of two exclusive licenses to close during June 2023.
PBI expects most license sales to generate - on average - about $1M in up-front fees.
3. Completion of Third (and Largest) Consumer Focus Group on Nano-THC
Two focus groups have validated the market transforming speed and dosing efficiency of PBI's Nano-THC.
Third focus group expected to further validate these results, plus super-fast pain relief from topical use.
4. John Westlake, Canopy CBD Farms ("CCF"), to Launch as Master Distributor of Nano-Cannabis Products
Assumes heightened role as a master distributor of PBIO nano-cannabis products in June 2023.
John/CCF delivers multiple sales channels, a deep nationwide industry network, and access to media and capital.
5. Initial Production Runs in PBIO's New Strategic Manufacturing Facilities
PBI's severe capacity limitations in current production facilities become relieved with new expansion transition into strategic partner Artisan Industries facilities, only 6 miles from PBI headquarters.
6. Dr. Denese Skin Science Collaboration Completes First Retinol Product R&D Phase - Expects Marketing LOI
Retinol-based anti-aging creams and serums are among the Dr. Denese Skin Science top sellers on QVC.
Dr. Denese believes PBIO's UltraShear nanoemulsification technology is the enabling platform for a revolutionary new generation of skincare.
PBI has completed the development of UltraShear-processed retinol with lipid-soluble Vitamin C formulations.
PBI anticipates a formal product marketing Letter-of-Intent (LOI) on these products with Dr. Denese in June.
Mr. Richard T. Schumacher, PBIO's President and CEO stated: "We have been laser-focused on making measurable progress on those areas that offer the best potential for rapid recurring revenue growth in the near future. I am pleased to say that the PBI Team has been highly successful in these endeavors. Progress on the six goals delineated here is a testament to their hard work and effectiveness - and to the value proposition of our UltraShear platform. All told, the incremental annual revenue expected from these goals, which our team expects to complete in June, should exceed several millions of dollars during the second half of FY 2023 alone, with incremental revenues growing further in FY 2024 and beyond."
Mr. Schumacher concluded: "We have accomplished a great deal in product development, technology demonstrations, and early commercial traction over the past year - and we believe that PBIO is highly undervalued at current market prices. We are continuing to help current and future investors understand the enormous potential of our many assets, especially our revolutionary (and diversely patented) Ultra Shear nanoemulsions technology platform."
New to The Street Signs Pressure BioSciences, Inc. To 12 Month TV Series, Agreement Includes Commercials and Billboard Ads
https://www.globenewswire.com/news-release/2023/06/01/2680506/0/en/New-to-The-Street-Signs-Pressure-BioSciences-Inc-To-12-Month-TV-Series-Agreement-Includes-Commercials-and-Billboard-Ads.html
NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- FMW Media's business TV show, New to The Street, announces the signing of a 12-month contract for filming and broadcasting tailored interviews and commercials about Pressure BioSciences, Inc. (OTCQB: PBIO) ($PBIO).
New to The Street’s TV anchors will interview the management team at PBIO with each show airing on New to The Street's televised syndicated outlets on Newsmax and Fox Business Network, sponsored program on Bloomberg TV, and website www.newtothestreet.com.
Pressure BioSciences, Inc. develops and sells innovative extreme pressure-based platform technology solutions for the global life sciences industry. The Company generates revenues from its patented platforms: Pressure Cycling Technology (“PCT™”), BaroFold™ Platform, and Ultra Shear Technology (“UltraShear™” or “UST™”).
With over 300 PCT installations worldwide, their Who’s Who of blue-chip customers spanning industry, academia and government are using PBIO products for vaccine developments, soil/plant biology applications, biotherapeutics, and diverse other life sciences applications. A wide array of scientific key opinion leaders underpins their credibility as their new UltraShear technology launches a new era of delivering oil-based nutrients and therapeutics, invisibly solubilized as nanoemulsions of oil in water.
The New to The Street’s social media team and television network partners will re-share media content, creating a platform to increase awareness about PBIO. All broadcasted shows will stream on the New to The Street website, www.newtothestreet.com. On a schedule, show previews and commercial ads will air on selected New to The Street syndicated and sponsored TV platforms. Digital ads will stream on New to The Street's billboard platform throughout New York City.
Richard T. Schumacher, President/CEO of Pressure BioSciences, Inc., states, “I look forward to appearing on New to The Street, to share our Company’s business success stories with viewers. PBIO commercializes its patented technologies to create and deploy products that are uniquely transformative in their markets. We are particularly excited about our UltraShear platform, now poised for explosive growth as a game-changer to the basis of competition across multiple diverse major markets. During each show, the objective will be to inform viewers about the Company growth strategies, current/ future products, and expected opportunities.”
TV viewers will hear about more about PBIO’s patented technologies, from PCT using alternating cycles of hydrostatic pressures to control biomolecular interactions and facilitate unprecedented scientific outcomes, to BaroFold controlling the critical refolding of proteins into active configurations for biopharmaceuticals, to UltraShear’s breakthroughs in speed and completeness of payload delivery across pharmaceuticals, nutraceuticals, cosmeceuticals, food/beverages, agrochem and other markets. Their platforms are gaining worldwide recognition, with customers daily increasing usage of their products from biomarker discovery to biopharmaceutical production to revolutions in treatment, nutrition, health and beauty.
Vince Caruso, CEO / Producer of New to The Street, states, "I am excited in having PBIO on the show for a 12-part TV series. They have patents, products, and a dedicated team that I believe our viewers will enjoy learning more about. With recognized scientific peer-reviewed publications about the Company’s products, and worldwide sales, the Company is positioned for a strong growth trajectory. The PBIO storyline is compelling, and I'm excited for the New to The Street audience to learn more about the Company."
New to The Street's TV interviews with Pressure BioSciences, Inc.’s management, airing on Newsmax (syndicated), Fox Business Network (syndicated), and Bloomberg TV (sponsored) "To Be Announced."
$PBIO Pressure BioSciences Announces Commercial Availability of Best-in-Class Nano-CBD Topical Spray, Featuring Lightning-Fast Action from PBI's UltraShear Processing
https://www.accesswire.com/756357/Pressure-BioSciences-Announces-Commercial-Availability-of-Best-in-Class-Nano-CBD-Topical-Spray-Featuring-Lightning-Fast-Action-from-PBIs-UltraShear-Processing
Leading CBD Retailer (CBD Supply MD) Today Introduces the "NanoBloom CBD" Topical Spray Through Their Mid-Atlantic Store Chain and Their Highly Effective, Nationwide, On-Line Retail Store
SOUTH EASTON, MA / ACCESSWIRE / May 22, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics nutraceuticals, cosmeceuticals, food and beverage, and other industries, and CBD Supply MD, one of the largest and best-known retail suppliers of CBD products in the multi-state mid-Atlantic region, today announced the commercial introduction and availability of their "NanoBloom CBD" Topical Spray, a leap forward in best-in-class, super-fast acting, highly bioavailable hemp-derived, all natural, CBD Topical Spray, also delivering rock solid multi-year stability.
NanoBloom CBD was formulated for ideal speedy effectiveness and optimal potency, finally addressing and resolving consumers' primary unmet objectives for CBD topical applications. In addition to its speed of action and potency breakthroughs, NanoBloom CBD is believed to be the only pharma-grade, preservative-free, all natural, Nano-CBD product available in the U.S. today, if not the world. The distribution agreement between the companies is for a minimum of two years and is expected to generate over $1.5 million in revenue for PBIO in the first year alone.
Mr. Keith E. Manley, Co-founder of CBD Supply MD, commented: "We are utterly thrilled and honored to introduce the first Ultra Shear Technology™ (UltraShear™ or UST™) processed product to the open market nationwide. Academic bioavailability data and consumer focus group feedback has convincingly demonstrated that PBIO's revolutionary UltraShear platform generates nanoemulsions of unmatched fast and complete bioavailability and long-term shelf stability, presenting a value proposition that is unparalleled in the industry. We are certain that the NanoBloom CBD product is destined to become a true game-changer. Happily, this is the first of many UltraShear nanoemulsified products we plan to bring to market with our new partner PBIO. As excited as this is for me personally and our CBD Supply MD team, I know our enthusiasm will pale in comparison to the benefits our customers are about to receive and understand."
Mr. John B. Hollister, Director of Sales and Marketing at PBIO, said: "CBD Supply MD is a highly respected market leader, with one of the largest established customer bases in the mid-Atlantic region, and with nationwide reach through their highly-effective website. We are excited that their customers will now have the opportunity to benefit from a best-in-class, UltraShear Nano-CBD product - in their NanoBloom CBD Topical Spray. We look forward to developing multiple additional product formulations with CBD Supply MD beyond this initial but substantial $1.5M CBD product agreement."
Mr. Richard T. Schumacher, PBIO's President and CEO summed up: "Our diverse work on UltraShear nanoemulsion processing across nutraceutical, cosmeceutical, pharmaceutical, agrochemical, and food/beverage markets has generated an exciting array of developing commercial opportunities for PBI. We are excited to announce initial commercialization with CBD Supply MD - and grateful to have the opportunity to work with such a highly respected retail sales leader in CBD products and the broader cannabis marketplace. We are negotiating with multiple companies interested in rights to our UltraShear processed nanoemulsion products and expect to announce a number of additional supply agreements in the coming weeks. All told, we expect that revenue from UltraShear processing in 2023 will quickly diversify across multiple major opportunities in nutraceuticals, cosmeceuticals and beyond, far exceeding revenue from all other PBIO products."
$PBIO Pressure BioSciences, Inc. Q1 2023 Financial Results Achieve All-Time Quarterly Record
https://www.accesswire.com/755225/Pressure-BioSciences-Inc-Q1-2023-Financial-Results-Achieve-All-Time-Quarterly-Record
Validated Nanoemulsion Capabilities Are Transformative Across Multiple Major Markets, New $1.5M Contract, New Manufacturing Facility, and Reduced Cash Burn Set Stage for Expected Strong FY 2023
Investor Call Scheduled for Tuesday May 16, 2023 at 4:30 p.m. ET
SOUTH EASTON, MA / ACCESSWIRE / May 16, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leader in the development and sale of broadly enabling, high pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food & beverage, and other industries, today reported that record quarterly financial results for any fiscal quarter was achieved in the first quarter ended March 31, 2023. The Company also provided a business update and offered guidance for expected pivotal achievements through 2023.
Financial Highlights: Q1 2023 vs. Q1 2022 (rounded to nearest hundredth, except EPS)
Total revenue for Q1 2023 was $740,600, an increase of 54% from $480,000 for Q1 2022.
Instrument sales for Q1 2023 were $427,500, an increase of 74% from $245,600 for Q1 2022.
Consumable sales for Q1 2023 were $66,400 compared to $40,000 for Q1 2022, an increase of 66%.
PBI Agrochem sales for Q1 2023 were $130,700 as compared to $83,300 for Q1 2022, an increase of 57%.
Operating loss for Q1 2023 was $3,637,700 compared to $1,086,300 for Q1 2022. This increase in operating loss was due to a non-cash expense of $1,480,900 for stock and warrant issuances to debt holders/professional services groups and to a non-cash expense of $1,430,200 for equity-based compensation awards.
Cash used from operations in Q1 2023 was $422,200 as compared to $756,300 in Q1 2022, a decrease of 44%.
Basic and diluted net loss per share was $(0.46) for Q1 2023, a decrease from $(0.48) from Q1 2022.
The Company reduced its cash burn from operations by 44% YoY to just $422,000 in the first quarter 2023, reflecting our ongoing focus on disciplined cash management. During Q1 of 2023, the Company issued several one-time stock issuances to certain debt holders and investor relations firms, to assist with critical corporate financing and development initiatives and public and private investor development. Management is confident that these investments will assist in focusing investor attention on our pivotal progress, as we proceed through commercialization of our UltraShear platform. During the quarter, the Company also issued stock options to employees and directors for the first time since 2019, recognizing the importance of incentive compensation in the retention of critical staff. The awards were issued at an above-market exercise price.
Q1 2022 and Recent Operational and Technical Highlights
May 9: Extended Consumer Testing Strongly Validates UltraShear Market Transforming Speed/Dosing Efficiency.
April 26: Company Updates Rapid Progress on Limited Offering of Exclusive UltraShear THC Licenses.
April 18: PBIO Announces Expansion into Strategic Manufacturing Facilities.
March 28: PBIO Reports Fresh Sales Momentum for PBI Agrochem.
March 22: PBIO Receives $1.5 Million Contract for UltraShear™ Nanoemulsified CBD.
March 1: Company Announces Exchange of Over $10 Million of Debt into Equity.
Feb 1: PBIO Receives Record Nearly $600,000 Single Order for 16 PCT Instruments.
Jan 27: PBIO and One World Products Announce Partnership in CBD-Nanoemulsion Sports Performance Drink.
Mr. John B. Hollister, Director of Marketing and Sales for PBIO, commented: "During the first quarter of 2023, the PBIO Team were terrifically effective in setting the stage for what we expect to be a year of rapid revenue growth, with significant expansion of both our customer base and product listing, strengthening of our financial framework, and recognition of our revolutionary UltraShear technology as the best-in-class nanoemulsion processing platform worldwide."
Mr. Richard T. Schumacher, President and CEO of PBI, stated: "Our anticipated ramping and expansion of UltraShear commercialization activities is now underway. We plan to ship the first production batch of Nano-CBD to our Maryland distributor for commercial sale within a week. The second batch - to a distributor in Massachusetts - should follow before the end of May. In addition, we have achieved important progress in the development of the next generation of anti-aging skincare, with our successful high quality nanoemulsification of oil-based retinol. We continue to progress smoothly towards our announced goal of developing several high-impact, market-changing products with extraordinarily potent bioavailability that we believe have never been available or commercialized until now: nanoemulsified hair replacement products, nanoemulsified immune booster products, and nanoemulsified sleep enhancement products. To our team of investors and employees, we share gratitude and anticipation over this exciting time to be a PBIO shareholder!"
If I wanted to send a man to the moon, I would want a cohort of scientists and engineers. If I wanted to evaluate the effectiveness of UST nano emulsion THC, I would want a cohort of (as you labeled them) potheads and not a group of scientist or engineers.
Yes, it was. Not to be confused by a round-table discussion by weed-heads, conducted by a weed-dealer, as being even close to a scientific discovery or achievement.
"Man, gimme a hit of that, huh. That's some good shit."
no SHORT here
Really?
So, the mission to land a man on the moon was not a cohort of like-minded scientist and engineers?
Cohort: A group of like-minded people sharing common characteristics.
No legitimate study EVER uses a cohort group. Not only do you not get any valid info from a "cohort", but the focus group was done by a cannabis marketing company.
$PBIO Pressure BioScience’s Pressure-Based Tech Is Ready To Spur Innovation And Growth In A Life Sciences Sector In Flux
https://www.accesswire.com/753930/Pressure-BioSciences-Pressure-Based-Tech-Is-Ready-To-Spur-Innovation-And-Growth-In-A-Life-Sciences-Sector-In-Flux
$PBIO Extended Consumer Testing Strongly Validates Market Transforming Speed and Dosing Efficiency of Pressure BioSciences UltraShear Processed Nano-THC Oral Spray
https://www.accesswire.com/753697/Extended-Consumer-Testing-Strongly-Validates-Market-Transforming-Speed-and-Dosing-Efficiency-of-Pressure-BioSciences-UltraShear-Processed-Nano-THC-Oral-Spray
Additional Focus Groups Corroborate UltraShear Nano-THC Produces Equal to Much Better THC Experiences, Even from Lower THC Dosing Levels; Also, Lightning-Fast Pain Relief from Topical Use.
SOUTH EASTON, MA / ACCESSWIRE / May 9, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or "Company") today announced results from additional consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks. The THC Nanoemulsion Oral Spray was prepared using PBI's revolutionary Ultra Shear Technology™ (UltraShear™) platform by PBI's California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products.
Additional consumer focus group testing more than doubled the original cohort of participants and has strongly affirmed multiple pivotal results on the UltraShear processed Nano-THC Oral Spray being powerfully differentiated from traditional THC dosing alternatives:
Speedy onset of first effects (average well under ten minutes - many reports in first few minutes) versus typical THC edibles requiring 30-60 minutes.
Much faster progression to maximum effects (average well under 40 minutes - many reports in 30 minutes or less) versus typical THC edibles requiring 60-120 minutes.
Eliminates health issues associated with smoking or vaping.
Enormous efficiency improvement in dose payload delivery allows equal to much better/greater THC experience from dosing down to a small fraction of user's normal dosing levels.
Stable, all plant formulation is sterile packaged with no added preservatives.
Multiple testers applied even a single spray to painful body areas and reported fast to instant transdermal pain relief.
Mr. John B. Hollister, PBIO's Director of Sales and Marketing, discussed highlights from the studies: "Most testing participants used lower doses of UltraShear Nano-THC than their usual dose level for THC products - and the vast majority of volunteers reported the same, more, or much more effect from the lower dosing of Nano-THC versus their normal dosing choices. Multiple normally heavy users of THC and many other participants reported onset of effects from the Nano-THC Oral Spray very quickly, even at significantly lower THC concentrations than usually consumed."
Mr. Hollister continued: "Following completion of the oral spray studies, we were also delighted by unplanned outcomes from multiple participants spraying the Nano-THC onto bodily pain locations (joint, arthritis, soreness, etc.) - and reporting very rapid, nearly instant relief from localized pain. All of these reported results are unsurprising to us, as scientific literature has long documented the greatly increased bioavailability of water-insoluble valuable constituents when dissolved into sufficiently small (under 100 nm) oil droplets. PBI's UltraShear platform accomplishes this with unmatched uniformity, tunable droplet size control, lower cost of production, better ease-of-use, and long-term stability."
Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: "These extended study results have confirmed the potential for a market transformation in THC consumption with a new oral/transdermal dosing modality in between the existing smoke/vape and edible food/beverage bifurcation of this enormous market. We believe that the customer experience with UltraShear processed Nano-THC will be compelling to drive a tidal change in the market, with potential explosive adoption of UltraShear processed Nano-THC."
Mr. Schumacher continued: "We are experiencing similar reactions and developments as we work with early partners across multiple other markets in nutraceuticals, cosmeceuticals, food/beverage, and more. 2023 is poised to be a watershed transformational year for PBI, as we capitalize for roll-out of the UltraShear platform and converge upon our announced NASDAQ or NYSE uplisting goal."
There are two revenue streams they are working on. Tolling and licensing UST. We'll see where this story goes in about a month. Q1 FY23 should be out soon.
First, they didn't just open up licensing a week ago----they announced it April 21, and posted an update April, 26. If; you think that companies will jump all over themselves to pay $1M for a 3 year license to produce/sell in only one State, and not own the equipment, when they can own the equipment and do what they want with it for ass long as they want, and for a very tiny fraction of the cost, you need to start thinking about Lotto and give up on equities.
Second, I'm not surprised that you haven't seen any dilution since you've been invested in PBIO. You're in love with the stock/company. In the 10k they had 13.6 million common shares on Dec. 31. They now have over 19 million common shares after just over 4 months. The debt for equity swap was “preferred” shares---not common shares. That's some serious dilution, and it's all because the company doesn't generate the cash needed to pay their debts and interest. So, you think that stock dilution to fund the company has not been their MO, huh? There are two ways to fund a company via stock dilution. 1) Have an ATM, and 2) trade common stock for debt/interest. PBIO uses #2.
Thirdly, I assume that you are pointing out, in error, that PBIO doesn't use surfacants or emulsifiers, but others do. Wrong again. Surfacants and emulsifiers are used to keep drops of ANY SIZE from coalescing when they come in contact with each other. Some emulsions need them, and other emulsions may not, and it has nothing to do with whether they are made with ultrasound or high pressure pump/valve. Industrial Sonomechanics has been selling their ultrasound nano-emulsifier for 6-7 years, and have had the time, and inclination, to develop their own as an OPTION, just as chillers are an OPTION. PBIO has yet to commercialize their UST equipment (the $75K Safer Medical order being the exception) .
You really need to 1) read, 2) understand, 3) think, before you post.
"Never fall in love with a stock; always have an open mind.".... Peter Lynch
“Never fall in love with a stock---rent the bitches---they might have the clap.”....Me
Sonomecnanics not the same.......
Customers who would like to produce translucent nanoemulsions of lipophilic (oil-soluble) bio-active compounds, such as cannabis extracts (a.k.a. water-soluble CBD and THC), vitamins, essential oils, terpenes, nutraceuticals and pharmaceuticals, but do not have the capability or desire to develop their own formulations and processing procedures can take advantage of our all-in-one NanoStabilizer®-LT. This proprietary blend of food-grade (GRAS) carrier oils, EMUSIFIERS, and preservatives (all derived from natural sources) is designed to work with ISM laboratory, bench and industrial ultrasonic processors and comes with step-by-step processing instructions. NanoStabilizer®-LT has no taste of its own and makes it possible to easily and quickly produce highly translucent, permanently stable and fully water-compatible nanoemulsions with median droplet sizes in the range of 10 – 50 nanometers.
PBIO opened up UST licensing a week ago. Per the PR it will take 15 to 60 days to close all 5 license agreements. I have not seen any significant dilution of shares over the time I have invested in PBIO. I think the leadership is very responsible in this regard. Yes, there was a 1:30 reverse split several years ago and the recent conversions of debt to equity. I think when PBIO is listed on a major exchange they will issue new shares to fund growth as necessary. What growth company doesn't do this? Stock dilution to fund the company has not been their MO. I see a new name added into the sales/marketing department as a contact for the UST licensing process.
Check their PR's again. They haven't sold any licenses yet. If they ever do, you can count on an 8K filed over it because it would be an "honest" material event.
Followers
|
59
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
28469
|
Created
|
12/19/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |